Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2438]

New targeted radionuclide alpha therapy improves prostate cancer outcomes

New targeted radionuclide alpha therapy improves prostate cancer outcomes

Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy

Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy

Scientists identify new — and very common — subtype of prostate cancer

Scientists identify new — and very common — subtype of prostate cancer

New cancer subtype may illuminate treatment strategy

New cancer subtype may illuminate treatment strategy

ECOG-ACRIN research highlights at ASCO 2022

ECOG-ACRIN research highlights at ASCO 2022

Not individual genes but the “mutational signatures” of many genes hold the key to better cancer therapies

Not individual genes but the “mutational signatures” of many genes hold the key to better cancer therapies

Common prostate cancer medications may be less safe than previously thought

Common prostate cancer medications may be less safe than previously thought

Men with prostate cancer have a higher risk of serious blood clots

Men with prostate cancer have a higher risk of serious blood clots

Benefits of PSA prostate cancer screening found to be more favourable than previous estimates, especially for blacks

Benefits of PSA prostate cancer screening found to be more favourable than previous estimates, especially for...

First mutation-targeted bladder cancer drug may be under-used

First mutation-targeted bladder cancer drug may be under-used

More from ecancer